Common Hereditary Cancers Panel Test code: 01102 • 10–21 days turnaround time 49 genes

Common Hereditary Cancers Panel Test code: 01102 • 10–21 days turnaround time 49 genes
$0.00

Common Hereditary Cancers Panel                    49 genes

This panel analyzes genes associated primarily with adult-onset, non-syndromic hereditary predisposition to cancer, including cancers of the breast, ovary, uterus, prostate, and gastrointestinal system.

Because these cancer types can have significant genetic heterogeneity, clinical characteristics, personal history, and family history alone may not always be sufficient to identify the underlying genetic cause. The overlapping clinical features of hereditary cancer conditions can make it challenging to determine which specific gene may be responsible based solely on the patient's presentation.

Broad panel testing allows for an efficient evaluation of multiple potential genes based on a single clinical indication. Identifying a hereditary genetic variant may provide valuable information for patients and their families and may help guide appropriate medical management.

Genetic testing may provide clinical value by helping to:

  • Confirm or clarify a clinical diagnosis

  • Identify an inherited predisposition to certain cancers

  • Help assess cancer risk

  • Inform appropriate screening and surveillance strategies

  • Help predict disease prognosis and progression

  • Support earlier detection of cancer or related symptoms

  • Inform family planning and genetic counseling

  • Identify potentially affected relatives who may benefit from genetic testing

  • Support consideration for relevant clinical trials

Some genes included in this panel may also be associated with additional medical conditions unrelated to hereditary cancer predisposition. These conditions are not included among the disorders specifically evaluated by this test.

Important Testing Information:
This panel is specifically designed to identify heritable germline genetic variants. It is not intended to detect somatic mutations in tumor tissue and should not be used as a substitute for tumor-based somatic testing.